Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that Prof. Jean-Yves Blay has been appointed to the Innate Pharma Supervisory Board.
Prof. Blay brings significant experience to the Innate Pharma Supervisory Board. He has held the post of General Director of the Centre Léon Bérard in Lyon, France, since 2014 and in 2016 became Secretary of the Oncology Commission of the French Academy of Medicine. Between 2009 and 2012 he held the position of President of the European Organisation for Research and Treatment of Cancer (EORTC).
“I am delighted to be joining the Supervisory Board,” commented Prof. Blay. “Innate Pharma is one of the leaders in the field of innate immunity, with an exciting pipeline that offers great opportunities in the immunotherapy of cancer.”
Hervé Brailly, Chairman of the Supervisory Board, added: “Jean-Yves’s wealth of experience in the research and treatment of cancer is a highly valuable addition to the Innate Pharma Supervisory Board, and we look forward to working closely with him as we advance more of our wholly-owned programs through clinical studies.”
Prof. Blay currently holds various other university and hospital positions. He is a member of the European Union Committee of Experts of Rare Disease, the European Commission’s Scientific Panel for Health (SPH) and served as a Faculty Coordinator for Sarcoma for the European Society of Medical Oncology (ESMO) between 2012 and 2016. Trained as a medical oncologist with a PhD from the University Claude Bernard in Lyon, his research activities have been focused on the role of immune effector cells and cytokines in cancer. Prof. Blay is a member of various scientific societies and academic expert groups, has been awarded several honors and is the author of more than 200 publications over the last three years.